{"id":468783,"date":"2022-12-20T00:00:00","date_gmt":"2022-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0009-2022-biopharma-type-1-diabetes-disease-landscape-forecast-g7-2022\/"},"modified":"2026-03-31T10:35:34","modified_gmt":"2026-03-31T10:35:34","slug":"dlsfmd0009-2022-biopharma-type-1-diabetes-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0009-2022-biopharma-type-1-diabetes-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Type 1 Diabetes | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes already on the market for type 2 diabetes (e.g., SGLT-2 inhibitors), but a few early-phase agents (e.g., VX-880) offer a novel mechanism of action. The emphasis has shifted on the types of therapies in development for T1D; interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors is significant. The availability of biosimilar insulins is also likely to have a sizable effect on the T1D therapy market throughout the G7, resulting in an intricate interplay of physician and payer attitudes toward this treatment option.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the drivers and constraints in the T1D market, and how will the market evolve over the forecast period?<\/li>\n<li>How are biosimilar insulins being adopted in the markets under study?<\/li>\n<li>What impact will the increasing use of insulin pumps have on market dynamics?<\/li>\n<li>How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the most clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?<\/li>\n<li>How will ultra-rapid insulins, such as Novo Nordisk\u2019s Fiasp and Eli Lilly\u2019s Lyumjev, be incorporated into treatment in the major markets?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies:<\/strong> United States, EU5, Japan.<\/p>\n<p><strong>Primary research:<\/strong> 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology:<\/strong> Prevalence of T1D by country with population-specific diagnosed and drug-treatment rates.<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key T1D therapies through 2031, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase III\/PR: 5 drugs; coverage of select preclinical, Phase I, and Phase II products.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>SOLUTION ENHANCEMENT<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-468783","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/468783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/468783\/revisions"}],"predecessor-version":[{"id":576156,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/468783\/revisions\/576156"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=468783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}